
FDA Approves Bayer Blood Thinner Asundexian for Stroke Prevention
The US Food and Drug Administration has approved Bayer's once-daily oral drug asundexian, sold under the brand name Sunharbo, to prevent recurrent strokes in high-risk patients. Prescribed alongside standard antiplatelet therapy, the therapeutic innovation offers a new biological pathway to protect patients who have suffered a serious vascular blockage or a transient mini stroke.
Giovanni SapereWith AI support · reviewed by Letizia Giugliano

















































































































































